The closely watched annual meeting of the American Society of Clinical Oncology (ASCO) is about to kick off in Chicago, and if the last few years are any indication, immunotherapy will likely steal the show. Cancer researchers have been perfecting all sorts of ways to stimulate patients’ immune systems to fight cancer, from chimeric antigen receptor T-cells (CARTs) now being tested in blood cancers, to “checkpoint inhibitors” like Bristol-Myers Squibb’s blockbuster melanoma treatment Yervoy (ipilimumab). But this year, an up-and-coming class of immune-boosting drugs could draw attention at ASCO—viruses that are specially engineered so they destroy tumors and then prime patients’ immune systems to continue fighting off their cancer.
Hey, check out all the research scientist jobs. Post your resume today!
